Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hepatology
Volume 2011, Article ID 545267, 8 pages
Case Report

Early Experience of Helical Tomotherapy for Hepatobiliary Radiotherapy

1Department of Radiation Oncology and Medical Physics, Institut Curie, 75005 Paris, France
2Department of Radiation Oncology, Institut Claudius Regaud, 31052 Toulouse, France
3Department of Radiology, Institut Curie, 75005 Paris, France
4Department of Radiation Oncology, European Georges Pompidou Hospital, 75015 Paris, Paris Descartes University, 75005 Paris, France

Received 14 April 2011; Accepted 14 May 2011

Academic Editors: A. Irisawa, C. Karaca, and B. Mauro

Copyright © 2011 Carole Massabeau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Helical tomotherapy (HT), an image-guided, intensity-modulated, radiation therapy technique, allows for precise targeting while sparing normal tissues. We retrospectively assessed the feasibility and tolerance of the hepatobiliary HT in 9 patients. A total dose of 54 to 60 Gy was prescribed (1.8 or 2 Gy per fraction) with concurrent capecitabine for 7 patients. There were 1 hepatocarcinoma, 3 cholangiocarcinoma, 4 liver metastatic patients, and 1 pancreatic adenocarcinoma. All but one patient received previous therapies (chemotherapy, liver radiofrequency, and/or surgery). The median doses delivered to the normal liver and to the right kidney were 15.7 Gy and 4.4 Gy, respectively, below the recommended limits for all patients. Most of the treatment-related adverse events were transient and mild in severity. With a median followup of 12 months, no significant late toxicity was noted. Our results suggested that HT could be safely incorporated into the multidisciplinary treatment of hepatobiliary or pancreatic malignant disease.